BRPI0911259A2 - composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos - Google Patents
composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostosInfo
- Publication number
- BRPI0911259A2 BRPI0911259A2 BRPI0911259A BRPI0911259A BRPI0911259A2 BR PI0911259 A2 BRPI0911259 A2 BR PI0911259A2 BR PI0911259 A BRPI0911259 A BR PI0911259A BR PI0911259 A BRPI0911259 A BR PI0911259A BR PI0911259 A2 BRPI0911259 A2 BR PI0911259A2
- Authority
- BR
- Brazil
- Prior art keywords
- vitro
- compounds
- compound
- pharmaceutical composition
- polymerase activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 101710112514 Host translation inhibitor 5b Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4521408P | 2008-04-15 | 2008-04-15 | |
| US4521908P | 2008-04-15 | 2008-04-15 | |
| US10985608P | 2008-10-30 | 2008-10-30 | |
| US11791608P | 2008-11-25 | 2008-11-25 | |
| US14833709P | 2009-01-29 | 2009-01-29 | |
| PCT/US2009/040567 WO2009134616A2 (en) | 2008-04-15 | 2009-04-14 | Novel inhibitors of hepatitis c virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911259A2 true BRPI0911259A2 (pt) | 2015-10-06 |
Family
ID=41078055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911259A BRPI0911259A2 (pt) | 2008-04-15 | 2009-04-14 | composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090257979A1 (enExample) |
| EP (1) | EP2283002A2 (enExample) |
| JP (1) | JP2011516610A (enExample) |
| KR (1) | KR20110004439A (enExample) |
| CN (1) | CN102026990A (enExample) |
| AU (1) | AU2009241514A1 (enExample) |
| BR (1) | BRPI0911259A2 (enExample) |
| CA (1) | CA2720846A1 (enExample) |
| MX (1) | MX2010011307A (enExample) |
| WO (1) | WO2009134616A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2056675T (lt) | 2006-10-12 | 2019-05-27 | Galera Labs, Llc | Burnos gleivinės mukozito gydymo būdai |
| CN102666537A (zh) * | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
| CA3120505C (en) | 2011-09-26 | 2024-11-12 | Galera Labs, Llc | METHODS OF TREATING DISEASES |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| WO2016148512A1 (ko) * | 2015-03-16 | 2016-09-22 | 마이크로엑츄에이터(주) | 카메라 모듈에 사용되는 필터전환 장치 및 카메라 모듈을 포함하는 모바일 기기 |
| UA126788C2 (uk) | 2015-08-11 | 2023-02-08 | Ґалера Лебз, Елелсі | Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| MX393974B (es) | 2016-05-03 | 2025-03-24 | Galera Labs Llc | Terapia de combinacion para tratamiento de cancer. |
| JP7166634B2 (ja) | 2016-09-01 | 2022-11-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法 |
| EA201992431A1 (ru) | 2017-10-13 | 2020-03-13 | ГАЛЕРА ЛЭБЗ, ЭлЭлСи | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6025984A (ja) * | 1983-07-22 | 1985-02-08 | Tokyo Inst Of Technol | ベンゾチアジアジン誘導体の製造方法 |
| JPH0216448A (ja) * | 1988-07-04 | 1990-01-19 | Fuji Photo Film Co Ltd | 化学物質の分配係数の推算処理方法 |
| CZ220498A3 (cs) * | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
| US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| US6156700A (en) * | 1997-09-17 | 2000-12-05 | American Cyanmid Company | 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3H)-pyrimidinone or thione herbicidal agents |
| US6943159B1 (en) * | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
| SI1560827T1 (sl) * | 2002-11-01 | 2011-04-29 | Abbott Lab | Antiinfekcijska sredstva |
| US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| US20040162285A1 (en) * | 2002-11-01 | 2004-08-19 | Pratt John K. | Anti-infective agents |
| US20040242568A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| WO2006021340A1 (en) * | 2004-08-23 | 2006-03-02 | F.Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2006093801A1 (en) * | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
| MX2007013415A (es) * | 2005-05-04 | 2008-01-15 | Hoffmann La Roche | Compuestos antivirales heterociclicos. |
| WO2007150001A1 (en) * | 2006-06-22 | 2007-12-27 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
| JP4199273B2 (ja) * | 2006-08-29 | 2008-12-17 | 本田技研工業株式会社 | 車両状態推定装置 |
| TW200840572A (en) * | 2006-12-12 | 2008-10-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
| US20080188466A1 (en) * | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| PT2118074E (pt) * | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| US20080227774A1 (en) * | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
| US7834009B2 (en) * | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
| TWI438206B (zh) * | 2008-06-10 | 2014-05-21 | Anadys Pharmaceuticals Inc | 〔１，２，４〕噻二１，１二氧化物化合物 |
-
2009
- 2009-04-14 CA CA2720846A patent/CA2720846A1/en not_active Abandoned
- 2009-04-14 WO PCT/US2009/040567 patent/WO2009134616A2/en not_active Ceased
- 2009-04-14 JP JP2011505149A patent/JP2011516610A/ja active Pending
- 2009-04-14 CN CN2009801168384A patent/CN102026990A/zh active Pending
- 2009-04-14 US US12/423,720 patent/US20090257979A1/en not_active Abandoned
- 2009-04-14 BR BRPI0911259A patent/BRPI0911259A2/pt not_active IP Right Cessation
- 2009-04-14 KR KR1020107025281A patent/KR20110004439A/ko not_active Withdrawn
- 2009-04-14 EP EP09739418A patent/EP2283002A2/en not_active Withdrawn
- 2009-04-14 MX MX2010011307A patent/MX2010011307A/es not_active Application Discontinuation
- 2009-04-14 AU AU2009241514A patent/AU2009241514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102026990A (zh) | 2011-04-20 |
| CA2720846A1 (en) | 2009-11-05 |
| WO2009134616A3 (en) | 2010-03-18 |
| WO2009134616A8 (en) | 2010-05-14 |
| JP2011516610A (ja) | 2011-05-26 |
| EP2283002A2 (en) | 2011-02-16 |
| AU2009241514A1 (en) | 2009-11-05 |
| US20090257979A1 (en) | 2009-10-15 |
| MX2010011307A (es) | 2010-11-09 |
| WO2009134616A2 (en) | 2009-11-05 |
| KR20110004439A (ko) | 2011-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911260A2 (pt) | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos | |
| BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
| BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| IL209258A (en) | Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
| EP2429987A4 (en) | AMID COMPOUND, PHARMACEUTICAL METHOD AND PHARMACEUTICAL COMPOSITION THEREFOR | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BRPI0915680A2 (pt) | miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos | |
| EP2286814A4 (en) | TRANSDERMALE PREPARATION WITH PALONOSETRON | |
| EP2157864A4 (en) | STABILIZED PICOPLATIN DOSAGE FORM | |
| BR112012003148A2 (pt) | composição de remoção de oxigênio, artigo,e, uso da composição de remoção de oxigênio | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BRPI0908859A2 (pt) | composição farmacêutica estabilizada de líquído único contedo docetaxel | |
| BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| AP3542A (en) | Anti-malarial pharmaceutical composition | |
| BR112012000379A2 (pt) | composições de matriz carreadora, métodos e usos | |
| EP2465512A4 (en) | PAIN-SUBJECTIVE PHARMACEUTICAL COMPOSITION | |
| BRPI1008019A2 (pt) | derivados de 6-(6-substituido-triazolo piridazina-sufanil) 5-flúor-benzo-tiazóis e 5-flúor-benzimidazóis: preparo, aplicação como medicamentos e utilização como inibidores de met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |